Medical Director, Infectious Diseases — Strategy Lead

Veloxis Pharmaceuticals, Inc.; North Carolina; Hybrid; USD 240,000 - 250,000; Full time

Benefits offered by this job

Health and insurance benefits

Training and development opportunities

Performance-based bonus eligibility

Job summary

Veloxis Pharmaceuticals, an Asahi‑Kasei Group company, seeks a Medical Director to lead the infectious diseases medical strategy with an initial focus on refractory herpes simplex virus (HSV) infections in immunocompromised patients.

The role is a core member of the Medical Affairs leadership team and partners closely with research, development, and corporate functions to advance the company’s therapeutic portfolio.

Qualifications

• MD or DO with Infectious Diseases specialization strongly preferred.
• 8 years’ experience in pharma/biotech, or 5+ years clinical/academic with industry collaboration.

Responsibilities

• Lead development and execution of the annual medical strategic plan with Medical Affairs leadership.
• Contribute to medical evidence-generation strategy (RWE, IIS, collaborative studies).
• Provide medical input into clinical development plans, TPPs, and lifecycle strategies.
• Build and maintain relationships with KOLs, academic experts, providers, patient groups, and payers to inform strategy.
• Act as internal medical advisor to cross-functional teams and committees.
• Support medical grant programs, HEOR, and market access efforts as appropriate.
• Collaborate with Medical Communications to ensure high-quality scientific communications.
• Monitor healthcare trends and ensure compliance and ethics in medical activities.

Skills

Leadership experience

Cross-functional collaboration

Communication skills

Travel readiness

Education

MD or DO with Infectious Diseases specialization

Alternative doctoral degree in health sciences (e.g., PharmD, Ph.D.)

Job description

Veloxis Pharmaceuticals, an Asahi‑Kasei Group company, seeks a Medical Director to lead the infectious diseases medical strategy with an initial focus on refractory herpes simplex virus (HSV) infections in immunocompromised patients.

The role is a core member of the Medical Affairs leadership team and partners closely with research, development, and corporate functions to advance the company’s therapeutic portfolio.